Tags : Adtralza

LEO Pharma’ Adtralza (tralokinumab) Receives EC’s Approval for Moderate-To-Severe Atopic

Tuba Khan June 23, 2021

Shots: The approval is based on efficacy & safety results from the P-III ECZTRA 1, 2 & 3 trials which evaluates Adtralza (300mg, SC) as monthx vs PBO in 1900+ […]readmore

Tags : Adtralza

LEO Pharma’ Adtralza (tralokinumab) Receives EC’s Approval for Moderate-To-Severe Atopic

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Adtralza

LEO Pharma’ Adtralza (tralokinumab) Receives EC’s Approval for Moderate-To-Severe Atopic

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company